Harvard Bioscience (HBIO) Liabilities from Discontinued Operations (2017)

Harvard Bioscience's (HBIO) quarterly Liabilities from Discontinued Operations came in at 1857000.0 in Q4 2017.

Harvard Bioscience (HBIO) Liabilities from Discontinued Operations (2017) Analysis & Trends

Harvard Bioscience (HBIO) has 1 years of Liabilities from Discontinued Operations data on file, last reported at 1857000.0 in Q4 2017.

On a quarterly basis, Liabilities from Discontinued Operations changed N/A year-over-year to 1857000.0 in Q4 2017; TTM through Dec 2017 was 1857000.0, a N/A change from a year earlier, with the FY2017 full-year figure at 1857000.0, changed N/A from the prior year.
Liabilities from Discontinued Operations for Q4 2017 stood at 1857000.0.
Over the last five years, Liabilities from Discontinued Operations for HBIO reached as high as 1857000.0 in Q4 2017 and fell as low as 1857000.0 in Q4 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alcon	32,734,969.19 Bn	32,734,967.53 Bn	1.53 Bn
2	Intuitive Surgical	117.50 Bn	112.41 Bn	1.96 Bn
3	Becton Dickinson	42.93 Bn	42.11 Bn	2.15 Bn
4	Medline	30.82 Bn	36.66 Bn	1.84 Bn
5	Resmed	27.90 Bn	26.23 Bn	890.98 Mn
6	West Pharmaceutical Services	26.76 Bn	26.23 Bn	329.20 Mn
7	Cooper Companies	15.30 Bn	15.16 Bn	735.40 Mn
8	Solventum	13.46 Bn	12.90 Bn	1.10 Bn
9	Align Technology	12.02 Bn	10.96 Bn	736.59 Mn
10	Harvard Bioscience	28.05 Mn	20.96 Mn	12.24 Mn

Download Data

Date	Value
Dec 31, 2017	1.86 Mn
Dec 31, 2017	1.86 Mn